Recent advances in the treatment of childhood obesity

R M Suskind1, U Blecker, J N Udall

  • 1The Chicago Medical School, North Chicago, IL 60064, USA. suskindr@mis.finchcms.edu

Pediatric Diabetes
|March 16, 2004
PubMed

Insights

This study shows a multidisciplinary weight management program effectively reduces obesity in children and adolescents. The program combined a protein-sparing modified fast (PSMF) diet, behavior modification, and exercise for significant results.

Area of Science:

  • Pediatric Endocrinology
  • Obesity Medicine
  • Clinical Nutrition

Background:

  • Rising childhood obesity rates necessitate effective interventions.
  • Previous treatments have shown limited long-term success.
  • Multidisciplinary approaches are promising for pediatric weight management.

Purpose of the Study:

  • To evaluate the efficacy of a multidisciplinary weight management program for obese children and adolescents.
  • To assess changes in body weight, body composition, and metabolic markers.
  • To determine the short-term effectiveness and sustainability of the intervention.

Main Methods:

  • A short-term clinical-outcome trial involving three groups of children and adolescents.
  • Intervention included a protein-sparing modified fast (PSMF) diet, behavior modification, and progressive exercise.
  • Measurements included weight, body fat percentage, VO2max, and lipid profiles at baseline and follow-up points.

Main Results:

  • Significant reductions in weight, ideal body weight percentage, and body fat percentage were observed at 10 weeks.
  • Weight loss was maintained at 26 and 36 weeks in different cohorts.
  • Improvements in cardiorespiratory fitness (VO2max) and beneficial changes in lipid profiles (lower TC, TG, LDL) were noted.

Conclusions:

  • A multidisciplinary weight management program incorporating PSMF, behavior modification, and exercise is effective for treating obesity in pediatric populations.
  • The intervention demonstrated positive short-term outcomes and maintenance of weight loss.
  • Further long-term, randomized controlled trials are warranted to confirm these findings.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.